X4 Pharmaceuticals announces 1-for-30 reverse stock split effective April 28 to regain Nasdaq bid price compliance

X4 Pharmaceuticals, Inc

Reverse stock split at 1-for-30 ratio effective 12:01 a.m. ET on April 28, 2025; shares trade split-adjusted under XFOR.
Outstanding shares reduced from ~173.6M to ~5.8M; no fractional shares issued, cash in lieu.
Split intended to cure Nasdaq minimum bid price deficiency; company received extension to August 11, 2025.
Proportional adjustments made to equity awards, options, and warrants; CUSIP changes to 98420X202.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

X4 Pharmaceuticals, Inc: Filed a certificate of amendment to effect a 1-for-30 reverse stock split of common stock, effective April 28, 2025 (effective 2025-04-28).

Change: charter amendment
Effective: 2025-04-28

Exact text from the filing

On April 24, 2025, X4 Pharmaceuticals, Inc. (the “Company”) filed an amendment (the “Certificate of Amendment”) to its Restated Certificate of Incorporation, as amended and/or restated from time to time, to effectuate a reverse stock split of the Company’s issued and outstanding shares of common stock, par value $0.001 per share (the “Common Stock”).

View on SEC.gov

101 governance changes filed in the last 30 days. Browse all governance changes →

X4 Pharmaceuticals, Inc filing history →

Source: SEC EDGAR

accession 0001628280-25-019507

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.